NexImmune, Inc.
NEXIHealthcare · Healthcare · <br>Emerging growth company · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|
| Revenue | — | — | $0 | $0 |
| Operating income | −$33.0M | −$63.1M | −$53.3M | −$27.9M |
| Net income | −$32.3M | −$62.5M | −$50.9M | −$29.9M |
| Total assets | $8.6M | $43.1M | $91.0M | $11.3M |
| Total liabilities | $5.1M | $10.8M | $7.3M | $27.1M |
| Equity | $3.5M | $32.3M | $83.8M | −$69.4M |
| EPS (diluted) | $-30.82 | $-64.95 | $-2.54 | $-26.42 |
| Shares out. | 26.1M | 1.0M | 22.8M | 1.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- —
- Net margin
- —
- Return on equity
- −921.6%
- Return on assets
- −376.4%
- Return on capital (ROCE)
- −939.5%
- Liabilities / assets
- 59.2%
- Debt / equity
- 1.45×
- Book value / share
- $0.13
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -109.26distress
- Accruals / assets
- −10.6%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 1 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2024
- NT 10-Kmissed a reporting deadline ↗Mar 29, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Jones KristiOfficer — President and CEO | Jun 11, 2024 | Buy | 1 | $0.01 |
| Roemer Alan S.Director | Nov 21, 2023 | Sell | 3,833 | $2.16 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 112 | 1.0 | 0.0% |
| Apr 30, 2026 | 112 | 1.0 | 0.0% |
| Apr 15, 2026 | 112 | 1.0 | 0.0% |
| Mar 31, 2026 | 112 | 1.0 | 0.0% |
| Mar 13, 2026 | 112 | 4.2 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Other material eventAug 27, 2024
- Shareholder voteAug 15, 2024
- Shareholder vote · Other material eventAug 2, 2024
- Shareholder vote · Other material eventJul 19, 2024
- Delisting / listing-standard notice · Shareholder vote · Other material eventJul 11, 2024
- Unregistered equity sale · Modified shareholder rights · Amended charter or bylawsJun 11, 2024
- Director / officer changeApr 5, 2024
- Entered a material agreement · Unregistered equity sale · Shareholder vote · Other material eventFeb 5, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.